| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	
 
																	
 
																	
 
																	Ardelyx (NASDAQ:ARDX) reported quarterly sales of $110.329 million which beat the analyst consensus estimate of $100.878 millio...
 
																	
 
																	IBSRELA patients reported treatment satisfaction in real-world surveyPost-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstra...
 
																	Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovati...
 
																	WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a missi...